辉瑞-BioNTech新冠疫苗接种后新发ANCA相关性血管炎一例
本文报告一例78岁既往肾功能正常的女性在接种辉瑞-BioNTech新冠疫苗后出现肾脏局限性ANCA相关性血管炎,表现为急性肾损伤、蛋白尿和镜下血尿,抗髓过氧化物酶抗体升高,肾活检示寡免疫复合物新月体坏死性肾小球肾炎,经激素和利妥昔单抗治疗后肾功能改善。作者指出该病例不能证明因果关系,但建议在全球疫苗接种期间持续监测类似并发症。
要点
- 接种辉瑞-BioNTech新冠疫苗后需警惕新发ANCA相关性血管炎。
- 表现为急性肾损伤、蛋白尿、镜下血尿及抗MPO抗体升高。
- 肾活检示寡免疫复合物新月体坏死性肾小球肾炎,激素联合利妥昔单抗可改善肾功能。
核心结论
- 报告一例既往肾功能正常的78岁女性在接种辉瑞-BioNTech新冠疫苗后新发肾脏局限性ANCA相关性血管炎。
- 该病例不能证明新冠疫苗接种与ANCA相关性血管炎之间的因果关系,但建议持续监测类似并发症。
研究设计与样本
- 病例报告:一例78岁女性,既往肾功能正常,接种辉瑞-BioNTech新冠疫苗后出现肾脏局限性ANCA相关性血管炎。
主要发现
- 患者出现急性肾损伤伴蛋白尿和镜下血尿,尿中见许多畸形红细胞。
- 抗髓过氧化物酶抗体滴度升高。
- 肾活检显示寡免疫复合物新月体坏死性肾小球肾炎。
- 经激素和利妥昔单抗治疗后肾功能改善。
- 患者接种前常规实验室检查正常。
临床怎么用
- 对接种新冠疫苗后出现急性肾损伤、蛋白尿或血尿的患者,应考虑评估ANCA相关性血管炎。
- 疑似病例应检测抗髓过氧化物酶抗体并进行肾活检以明确诊断。
局限性
- 单例病例报告不能确立新冠疫苗接种与ANCA相关性血管炎之间的因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread around the world. As of the end of June 2021, there were approximately 181 million confirmed cases and more than 3.9 million deaths across the globe. The colossal impact of coronavirus disease 2019 (COVID-19) is driving the biggest vaccination campaign in human history. All 3 vaccines authorized for emergency use by the US Food and Drug Administration (Pfizer-BioNTech, Moderna, and Janssen/Johnson & Johnson) have been thoroughly studied and found to be safe and effective in preventing severe COVID-19 cases. While short-term side effects of COVID-19 vaccine resemble those of other vaccines, long-term side effects remain unknown. Rare side effects continue to surface as millions of people receive COVID-19 vaccines around the world, as compared with the thousands enrolled in the clinical trials. We report a case of new-onset renal-limited ANCA-associated vasculitis (AAV) in a 78-year-old woman with previously normal kidney function after receiving the Pfizer-BioNTech COVID-19 vaccine. The patient developed acute kidney injury with proteinuria and microscopic hematuria with many dysmorphic red blood cells in the urine. Anti-myeloperoxidase antibody titer was elevated. Kidney biopsy showed pauci-immune crescentic necrotizing glomerulonephritis. Kidney function improved after treatment with steroids and rituximab. Our patient had normal routine laboratory testing before the vaccination. Although this case cannot demonstrate a causal relationship between COVID-19 vaccination and AAV, ongoing surveillance for similar complications would be prudent as worldwide vaccination efforts continue.
引用
- Shakoor MT, Birkenbach MP, Lynch M, et al. ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine. Am J Kidney Dis. 2021. PMID: 34280507. doi:10.1053/j.ajkd.2021.06.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。